Rx-360 Establishes Asia Working Group - India
Rx-360, an international, non-profit supply chain consortium, has announced, the formation of the Rx-360 Asia Working Group – India. The Working Group will be led by Anish Swadi, Vice President, Business Development at Hikal, Huzefa Hussain, Manager-Quality Assurance at Amgen, and Prashant Wani, Senior Supplier Auditor at Eli Lilly & Company. The Working Group held an initial face-to-face meeting in Mumbai, India on 24 February 2015. Meeting attendees were from global and local India pharmaceutical and supplier companies.
The Rx-360 Working Group - Asia has had a vibrant group in Shanghai for almost 2 years. Given the size of India’s pharma market and its importance as a manufacturer and exporter of APIs and drug product to North America and Europe, Rx-360 believed it was important to also develop a presence in India.
The Working Group will focus its attention on identifying and mitigating root causes of quality problems and supply chain security. As a neutral, open, and consensus building industry forum, Rx-360 seeks to help address these quality challenges and support India industry.
The Working Group's goals are to
• build Rx-360’s reputation and credibility in India as a group with tools to solve problems relevant to the global pharma industry and supply chain
• help understand and mitigate root causes of the most pressing quality challenges
• share best practices and case studies from sites
• spread awareness and understanding about Rx-360, its activities, and its audit programs, in India among India-based suppliers and manufacturers
• position Rx-360 as a mentoring resource for the India pharma industry.
The Rx-360 India Working Group has prepared a survey to solicit feedback from individuals who may have encountered data integrity (DI) issues in the course of their work in GMP sites located in India. The purpose of this survey is to benchmark experiences and mitigation strategies. The survey is voluntary, confidential and anonymous. Results of the survey will be shared individually with participating companies. The intent of the survey is to gather benchmarking information to develop educational materials and other efforts that can help to advance data integrity understanding and mitigations.
To access the survey, please click here
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance